The animal and food safety company Neogen bought the agricultural trait selection business to enhance its genomics-based diagnostics products.
Through the transaction, MDRNA will gain Cequent's orally delivered transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.
Luminex's acquisition of BSD Robotics will provide it with new technologies in automation and robotics in the field of dry sample handling.
Genetix will operate as a separate business unit within Danaher subsidiary Leica Microsystems.
The sale of the product lines to Bruker will clear the way for Agilent to complete its $1.5 billion acquisition of Varian, which is now expected by the end of April.
Thermo completed the acquisition of the Finland-based maker of reagents, consumables, kits, and instruments for molecular biology applications.
The $7.2 billion deal would create a life sciences tools and pharmaceutical firm with annual revenues of nearly $3 billion.
PerkinElmer has purchased the ICP-MS joint venture from Danaher that was at the center of PerkinElmer's earlier legal action against MDS.
Two days after reports that Thermo Fisher Scientific had made a $6 billion bid for the firm, Millipore confirmed it is evaluating strategic alternatives.
The firms would not confirm the offer, but two news agencies have claimed that sources have verified that the bid has been made.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.